


AMENDMENTS TO THE CLAIMS

1. (Previously Presented) A chemical compound having the formula



in labelled or unlabelled form, or any of its enantiomers or any mixture thereof, or a pharmaceutically acceptable salt thereof;

R represents hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, a mono- or polycyclic aryl group, or aralkyl; and

R¹ represents a bi-cyclic heterocyclic group selected from the group consisting of 5- or 6-benzimidazolyl, 5- or 6-benzofuranyl, 5- or 6-benzothiazolyl, 5- or 6-benzothienyl, 5- or 6-benzotrizolyl, 6- or 7-cinnolinyl, 5- or 6-indazolyl, 5- or 6-indoliziny, 5- or 6-indolyl, 5- or 6-isoindolyl, 6- or 7-isoquinolinyl, 6-phthalazinyl, 6- or 7-quinolinyl, 6- or 7-quinoliziny, and 6- or 7-quinoxaliny; which heterocyclic groups may be substituted one or more times with substituents selected from the group consisting halogen, amino, hydroxy, alkoxy, alkoxy-alkyl, alkoxy-alkoxy, sulfanyl, alkylsulfanyl, alkylsulfanyl-alkoxy, alkoxy-alkylsulfanyl, and alkylsulfanyl-alkylsulfanyl.

2-10. (Cancelled)

11. (Previously Presented) The chemical compound of claim 1, wherein R¹ represents a bi-cyclic heterocyclic group selected from the group consisting of 5- or 6-benzimidazolyl, 5- or 6-benzofuranyl, 5- or 6-benzothiazolyl, 5- or 6-benzothienyl, 5- or 6-benzotrizolyl, 6- or 7-cinnolinyl, 5- or 6-indazolyl, 5- or 6-indoliziny, 5- or 6-indolyl, 5- or 6-isoindolyl, 6- or 7-isoquinolinyl, 6-phthalazinyl, 6- or 7-quinolinyl, 6- or 7-quinoliziny, and 6- or 7-quinoxaliny; which heterocyclic groups may be substituted one or more times with substituents selected from the group consisting of halogen, amino, hydroxy, alkoxy, alkoxy-alkyl, alkoxy-alkoxy, sulfanyl, alkylsulfanyl, alkylsulfanyl-alkoxy, alkoxy-alkylsulfanyl, and alkylsulfanyl-alkylsulfanyl.

12-26. (Cancelled)

39. (Previously Presented) A compound selected from the group consisting of:

(±)-3-[6-Isoquinolinyl]-8-methyl-8-azabicyclo[3.2.1]oct-2-ene;

(±)-3-[6-Quinolinyl]-8-methyl-8-azabicyclo[3.2.1]oct-2-ene;

(±)-3-[7-Isoquinolinyl]-8-methyl-8-azabicyclo[3.2.1]oct-2-ene;

(±)-3-[7-Quinolinyl]-8-methyl-8-azabicyclo[3.2.1]oct-2-ene;

(±)-3-[1-H-5-Benzimidazolyl]-8-methyl-8-azabicyclo[3.2.1]oct-2-ene;

(±)-3-[1-H-6-Benzimidazolyl]-8-methyl-8-azabicyclo[3.2.1]oct-2-ene;

(±)-3-[1-H-5-Benzotrizolyl]-8-methyl-8-azabicyclo[3.2.1]oct-2-ene;

(±)-3-[1-H-6-Benzotrizolyl]-8-methyl-8-azabicyclo[3.2.1]oct-2-ene;
(±)-3-[2-Amino-1-H-5-benzimidazolyl]-8-methyl-8-azabicyclo[3.2.1]oct-2-ene;
(±)-3-[2-Amino-1-H-6-benzimidazolyl]-8-methyl-8-azabicyclo[3.2.1]oct-2-ene;
(±)-3-[6-phthalazinyl]-8-methyl-8-azabicyclo[3.2.1]oct-2-ene;
(±)-3-[5-Benzofuranyl]-8-methyl-8-azabicyclo[3.2.1]oct-2-ene;
(±)-3-[6-Benzofuranyl]-8-methyl-8-azabicyclo[3.2.1]oct-2-ene;
(±)-3-[5-Benzothienyl]-8-methyl-8-azabicyclo[3.2.1]oct-2-ene;
(±)-3-[6-Benzothienyl]-8-methyl-8-azabicyclo[3.2.1]oct-2-ene;
(±)-3-[5-Benzothiazolyl]-8-methyl-8-azabicyclo[3.2.1]oct-2-ene;
(±)-3-[6-Benzothiazolyl]-8-methyl-8-azabicyclo[3.2.1]oct-2-ene;
(±)-3-[1-Methyl-5-indolyl]-8-methyl-8-azabicyclo[3.2.1]oct-2-ene;
(±)-3-[1-Methyl-6-indolyl]-8-methyl-8-azabicyclo[3.2.1]oct-2-ene;
(±)-3-[5-Indoliziny]-8-methyl-8-azabicyclo[3.2.1]oct-2-ene;
(±)-3-[6-Indoliziny]-8-methyl-8-azabicyclo[3.2.1]oct-2-ene;
(±)-3-[2-Methyl-5-isoindolyl]-8-methyl-8-azabicyclo[3.2.1]oct-2-ene;
(±)-3-[2-Methyl-6-isoindolyl]-8-methyl-8-azabicyclo[3.2.1]oct-2-ene;
(±)-3-[1-Methyl-5-indazolyl]-8-methyl-8-azabicyclo[3.2.1]oct-2-ene;
(±)-3-[1-Methyl-6-indazolyl]-8-methyl-8-azabicyclo[3.2.1]oct-2-ene;
(±)-3-[6-Quinoliziny]-8-methyl-8-azabicyclo[3.2.1]oct-2-ene;
(±)-3-[7-Quinoliziny]-8-methyl-8-azabicyclo[3.2.1]oct-2-ene;

(±)-3-[6-Cinnolinyl]-8-methyl-8-azabicyclo[3.2.1]oct-2-ene;
(±)-3-[7-Cinnolinyl]-8-methyl-8-azabicyclo[3.2.1]oct-2-ene;
(±)-3-[6-Quinoxaliny]l]-8-methyl-8-azabicyclo[3.2.1]oct-2-ene; or
(±)-3-[7-Quinoxaliny]l]-8-methyl-8-azabicyclo[3.2.1]oct-2-ene;
or a pharmaceutically acceptable addition salt thereof.